SURFACE ONCOLOGY INC (SURF) Stock Price, Quote, News and Overview
NASDAQ:SURF - Nasdaq - US86877M2098 - Common Stock - Currency: USD
SURF Quote, Performance and Key Statistics
1.07
-0.01 (-0.93%)
The current stock price of SURF is 1.07 USD. In the past month the price increased by 16.3%. In the past year, price decreased by -21.9%.
SURF Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SURF
Company Profile
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-04-19. The firm is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
Company Info
SURFACE ONCOLOGY INC
50 Hampshire Street, 8Th Floor
Cambridge MASSACHUSETTS 02139 US
CEO: J. Jeffrey Goater
Employees: 60
Company Website: https://www.surfaceoncology.com/
Phone: 16177144096.0
SURFACE ONCOLOGY INC / SURF FAQ
What is the stock price of SURFACE ONCOLOGY INC today?
The current stock price of SURF is 1.07 USD. The price decreased by -0.93% in the last trading session.
What is the ticker symbol for SURFACE ONCOLOGY INC stock?
The exchange symbol of SURFACE ONCOLOGY INC is SURF and it is listed on the Nasdaq exchange.
On which exchange is SURF stock listed?
SURF stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SURFACE ONCOLOGY INC stock?
11 analysts have analysed SURF and the average price target is 2.43 USD. This implies a price increase of 127.19% is expected in the next year compared to the current price of 1.07. Check the SURFACE ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SURFACE ONCOLOGY INC worth?
SURFACE ONCOLOGY INC (SURF) has a market capitalization of 65.08M USD. This makes SURF a Micro Cap stock.
How many employees does SURFACE ONCOLOGY INC have?
SURFACE ONCOLOGY INC (SURF) currently has 60 employees.
What are the support and resistance levels for SURFACE ONCOLOGY INC (SURF) stock?
SURFACE ONCOLOGY INC (SURF) has a support level at 1.01 and a resistance level at 1.09. Check the full technical report for a detailed analysis of SURF support and resistance levels.
Is SURFACE ONCOLOGY INC (SURF) expected to grow?
The Revenue of SURFACE ONCOLOGY INC (SURF) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SURF EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SURFACE ONCOLOGY INC (SURF) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SURF, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SURF, evaluating the profitability, health, valuation and growth aspects
- SURFACE ONCOLOGY INC (SURF) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SURFACE ONCOLOGY INC (SURF) Sales and EPS estimates to see what analysts future expectations are.
- SURFACE ONCOLOGY INC (SURF) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SURFACE ONCOLOGY INC (SURF) Insider and Institutional Ownership to learn about the owners and their transactions.
- SURFACE ONCOLOGY INC (SURF) Stock Chart to make your own analysis
- SURFACE ONCOLOGY INC (SURF) Latest news and press-releases to stay up to date.
Does SURFACE ONCOLOGY INC (SURF) stock pay dividends?
SURF does not pay a dividend.
When does SURFACE ONCOLOGY INC (SURF) report earnings?
SURFACE ONCOLOGY INC (SURF) will report earnings on 2023-10-31, before the market open.
What is the Price/Earnings (PE) ratio of SURFACE ONCOLOGY INC (SURF)?
SURFACE ONCOLOGY INC (SURF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
SURF Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SURF. When comparing the yearly performance of all stocks, SURF is one of the better performing stocks in the market, outperforming 78.67% of all stocks.
SURF Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SURF. While SURF seems to be doing ok healthwise, there are quite some concerns on its profitability.
SURF Financial Highlights
Over the last trailing twelve months SURF reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS decreased by -18.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SURF Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to SURF. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -41.08% and a revenue growth -100% for SURF